Microbiology of febrile neutropenia: European data on incidence and resistance

International Journal of Hematology

Volumn 68, Issue SUPPL. 1, 1998, Pages

  Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; METICILLIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; EUROPE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; INCIDENCE; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPENIA; PATHOGENICITY; PRIORITY JOURNAL;

DRUG RESISTANCE, MICROBIAL; EUROPE; FEVER; HUMANS; INCIDENCE; NEUTROPENIA;

EID: 0031736419     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. EORTC-National Cancer Institute of Canada. Vancomycin added to Empirical Combination Antibiotic Therapy for Fever in Granulocytopenic Cancer Patients. J Infect Dis 1991;163:951-958.
2. Viscoli C et al. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1994;30 A:430-437.
3. Rossi C et al. Initial Empirical Antibiotic Therapy for Neutropenic Fever: Analysis of the Causes of Death. Supp Care Cancer 1996;4:207-212.
4. De Paw BE et al. Empirical and Subsequent use of Antibacterial Agents in the Febrile Neutropenic Patient. J Intern Med 1997;242(suppl. 740):69-77.
5. Cordonier C et al. Cefepime/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Febrile Episodes in Neutropenic Patients: A comparative Study. Clin Infect Dis 1997;24:41-51.